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In this issue of American Family Physician, 
DiCola and Spaar give pragmatic guidance to 
family physicians on their role in responding 
to patients who are experiencing intimate part-
ner violence (IPV).1 Their approach accords 
with the U.S. Preventive Services Task Force 
recommendation to screen all women for IPV. 
The United States is one of the few countries 
with a policy of screening for IPV. Guidelines 
from the United Kingdom’s National Insti-
tute for Health and Care Excellence2 and the 
World Health Organization3 recommend a 
low threshold for physicians to ask about IPV, 
but do not recommend routine screening. 
The evidence for screening in health care set-
tings is contradictory, hence the discrepancy 
between the systematic review underpinning 
the U.S. Preventive Services Task Force guide-
lines4 and the Cochrane review on which the 
National Institute for Health and Care Excel-
lence guidelines are based.5,6 
I propose that we move beyond this debate, 
particularly in the context of family medi-
cine, and focus instead on action that will 
protect the safety of patients experiencing 
IPV. My rationale for this proposal is twofold.
First, screening programs are not all that 
different from targeted inquiry approaches. 
We know that screening programs increase 
disclosure of IPV in health care settings. We 
also know that training family physicians 
to ask about IPV, particularly when there 
is a referral pathway to further support the 
patient, also increases disclosure.7 There are 
no head-to-head trials of screening vs. clini-
cal inquiry (or active case finding), so we do 
not know which is more effective. Given that 
even in trials screening by physicians is only 
partial, in reality, the operational differ-
ence in the family medicine clinic between 
an IPV screening program and a targeted 
clinical inquiry program is likely to be mini-
mal. Physicians do not implement screening 
not only because of time constraints, lack of 
training, and discomfort with asking about 
abuse, which would affect any IPV identi-
fication method, but also because they are 
skeptical about the evidence base.8
Second, the IPV screening vs. active case 
finding debate is a distraction for research-
ers, systematic reviewers, and physicians, 
because it focuses attention and resources 
on what is only the first step in an effective 
(and safe) response to survivors of IPV in 
clinical settings. The ensuing steps after a 
patient has disclosed abuse to a physician 
(or physician’s assistant or nurse) are as 
important as eliciting disclosure, regardless 
of the identification method. These steps 
include the physician giving an appropriate 
and validating response, checking for safety, 
offering referral to IPV support agencies, 
facilitating uptake of that referral (i.e., more 
than just offering a list of agencies), and 
offering ongoing physician contact.
What is the thread that ties effective iden-
tification of IPV survivors to effective man-
agement? Training. Given the absence or low 
profile of undergraduate or postgraduate 
medical training on IPV, how can we expect 
physicians and other clinicians to engage 
with the issue? They often do not under-
stand the epidemiology of IPV, its coercive 
reality, the entrapment of survivors, and the 
severe safety risks, which may inhibit disclo-
sure of the abuse or use of support services. 
Asking about IPV in a family medicine set-
ting, via a screening tool or in the course of 
taking a clinical history, requires training 
and practice. A systematic review of nine 
trials of IPV training interventions for phy-
sicians showed that only multifaceted physi-
cian training that combined education with 
system support interventions changed physi-
cian behavior related to IPV. System support 
activities included displaying posters and 
brochures about violence in waiting areas, 
and providing prompts to physicians, check-
lists in medical records for IPV diagnosis, 
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and information on accessing services and referral 
for patients. 
In the United States and internationally, we need 
to prioritize effective IPV training of physicians 
and other clinicians, whatever guidelines we use to 
identify IPV survivors. If they do not exist already, 
we need to establish explicit referral pathways to IPV 
advocacy support, which may be outside of health 
care organizations in the social care or community 
nonprofit sectors. 
Physician offices may be one of the few safe spaces 
for patients to disclose their abuse. We know that 
survivors want us to ask about IPV and to respond 
appropriately and safely.9 Training and system sup-
port will allow us to do that. 
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INDICATIONS AND USAGE
Fluzone High-Dose is a vaccine indicated for active immunization for the prevention of influenza disease 
caused by influenza A subtype viruses and type B virus contained in the vaccine. Fluzone High-Dose is 
approved for use in persons 65 years of age and older. 
DOSAGE AND ADMINISTRATION
For intramuscular use only
Dose and Schedule
Fluzone High-Dose should be administered as a single 0.5 mL injection by the intramuscular route in 
adults 65 years of age and older.
Administration
Inspect Fluzone High-Dose visually for particulate matter and/or discoloration prior to administration. 
If either of these conditions exist, the vaccine should not be administered. Before administering a dose 
of vaccine, shake the prefilled syringe. The preferred site for intramuscular injection is the deltoid 
muscle. The vaccine should not be injected into the gluteal area or areas where there may be a 
major nerve trunk. Do not administer this product intravenously or subcutaneously. Fluzone High-Dose 
should not be combined through reconstitution or mixed with any other vaccine.
DOSAGE FORMS AND STRENGTHS
Fluzone High-Dose is a suspension for injection. Fluzone High-Dose is supplied in prefilled syringes (gray 
syringe plunger rod), 0.5 mL, for adults 65 years of age and older.  
CONTRAINDICATIONS
A severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or 
to a previous dose of any influenza vaccine is a contraindication to administration of Fluzone High-Dose.
WARNINGS AND PRECAUTIONS
Guillain-Barré Syndrome
If Guillain-Barré syndrome (GBS) has occurred within 6 weeks following previous influenza vaccination, 
the decision to give Fluzone High-Dose should be based on careful consideration of the potential benefits 
and risks. The 1976 swine influenza vaccine was associated with an elevated risk of GBS. Evidence for a 
causal relation of GBS with other influenza vaccines is inconclusive; if an excess risk exists, it is probably 
slightly more than 1 additional case per 1 million persons vaccinated.1,2 
Preventing and Managing Allergic Reactions
Appropriate medical treatment and supervision must be available to manage possible anaphylactic 
reactions following administration of the vaccine. 
Altered Immunocompetence
If Fluzone High-Dose is administered to immunocompromised persons, including those receiving 
immunosuppressive therapy, the expected immune response may not be obtained.
Limitations of Vaccine Effectiveness
Vaccination with Fluzone High-Dose may not protect all recipients. 
ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse event rates observed 
in the clinical trial(s) of a vaccine cannot be directly compared to rates in the clinical trial(s) of another 
vaccine and may not reflect the rates observed in practice. Two clinical studies have evaluated the 
safety of Fluzone High-Dose. Study 1 (NCT00391053, see http://clinicaltrials.gov) was a multi-center, 
double-blind pre-licensure trial conducted in the US. In this study, adults 65 years of age and older 
were randomized to receive either Fluzone High-Dose or Fluzone (2006-2007 formulation). The study 
compared the safety and immunogenicity of Fluzone High-Dose to those of Fluzone. The safety analysis 
set included 2573 Fluzone High-Dose recipients and 1260 Fluzone recipients. 
Table 1 summarizes solicited injection-site reactions and systemic adverse events reported within 7 days 
post-vaccination via diary cards. Onset was usually within the first 3 days after vaccination and a majority 
of the reactions resolved within 3 days. Solicited injection-site reactions and systemic adverse events were 
more frequent after vaccination with Fluzone High-Dose compared to Fluzone.
Table 1: Study 1a: Frequency of Solicited Injection-Site Reactions and Systemic Adverse Events Within 







Any Moderatec Severed Any Moderatec Severed
Injection-Site Pain  35.6  3.7  0.3  24.3  1.7  0.2
Injection-Site Erythema  14.9  1.9  1.8  10.8  0.8  0.6
Injection-Site Swelling  8.9  1.6  1.5  5.8  1.3  0.6
Myalgia  21.4  4.2  1.6  18.3  3.2  0.2
Malaise  18.0  4.7  1.6  14.0  3.7  0.6
Headache  16.8  3.1  1.1  14.4  2.5  0.3
Fevere (≥99.5°F)  3.6  1.1  0.0  2.3  0.2  0.1
a NCT00391053
b N is the number of vaccinated participants with available data for the events listed
c  Moderate - Injection-site pain: sufficiently discomforting to interfere with normal behavior or activities; 
Injection-site erythema and Injection-site swelling: ≥2.5 cm to <5 cm; Fever: >100.4°F to ≤102.2°F; 
Myalgia, Malaise, and Headache: interferes with daily activities
d  Severe - Injection-site pain: incapacitating, unable to perform usual activities; Injection-site erythema and 
Injection-site swelling: ≥5 cm; Fever: >102.2°F; Myalgia, Malaise, and Headache: prevents daily activities
e  Fever - The percentage of temperature measurements that were taken by oral route or not recorded were 
97.9% and 2.1%, respectively, for Fluzone High-Dose; and 98.6% and 1.4%, respectively, for Fluzone
Within 6 months post-vaccination, 156 (6.1%) Fluzone High-Dose recipients and 93 (7.4%) Fluzone 
recipients experienced a serious adverse event (SAE). No deaths were reported within 28 days post-
vaccination. A total of 23 deaths were reported during Days 29–180 post-vaccination: 16 (0.6%) among 
Fluzone High-Dose recipients and 7 (0.6%) among Fluzone recipients. The majority of these participants 
had a medical history of cardiac, hepatic, neoplastic, renal, and/or respiratory diseases. These data do 
not provide evidence for a causal relationship between deaths and vaccination with Fluzone High-Dose.
Study 2 (NCT01427309, see http://clinicaltrials.gov) was a multi-center, double-blind post-licensure 
efficacy trial conducted in the US and Canada over two influenza seasons. In this study, adults 65 years of 
age and older were randomized to receive either Fluzone High-Dose or Fluzone (2011-2012 and 2012-2013 
formulations). The study compared the efficacy and safety of Fluzone High-Dose to those of Fluzone. The 
safety analysis set included 15,992 Fluzone High-Dose recipients and 15,991 Fluzone recipients.
Within the study surveillance period (approximately 6 to 8 months post-vaccination), 1323 (8.3%) Fluzone 
High-Dose recipients and 1442 (9.0%) Fluzone recipients experienced an SAE. Within 30 days post-
vaccination, 204 (1.3%) Fluzone High-Dose recipients and 200 (1.3%) Fluzone recipients experienced an 
SAE. The majority of these participants had one or more chronic comorbid illnesses. A total of 167 deaths 
were reported within 6 to 8 months post-vaccination: 83 (0.5%) among Fluzone High-Dose recipients and 
84 (0.5%) among Fluzone recipients. A total of 6 deaths were reported within 30 days post-vaccination: 
6 (0.04%) among Fluzone High-Dose recipients and 0 (0%) among Fluzone recipients. These data do 
not provide evidence for a causal relationship between deaths and vaccination with Fluzone High-Dose.
Post-Marketing Experience
The following events have been spontaneously reported during the post-approval use of Fluzone or 
Fluzone High-Dose. Because these events are reported voluntarily from a population of uncertain 
size, it is not always possible to reliably estimate their frequency or establish a causal relationship to 
vaccine exposure. Adverse events were included based on one or more of the following factors: severity, 
frequency of reporting, or strength of evidence for a causal relationship to Fluzone or Fluzone High-Dose.
Events Reported During Post-Approval Use of Fluzone.
• Blood and Lymphatic System Disorders : Thrombocytopenia, lymphadenopathy
•  Immune System Disorders : Anaphylaxis, other allergic/hypersensitivity reactions (including urticaria, 
angioedema)
• Eye Disorders : Ocular hyperemia
•  Nervous System Disorders : Guillain-Barré syndrome (GBS), convulsions, febrile convulsions, myelitis 
(including encephalomyelitis and transverse myelitis), facial palsy (Bell’s palsy), optic neuritis/
neuropathy, brachial neuritis, syncope (shortly after vaccination), dizziness, paresthesia
• Vascular Disorders : Vasculitis, vasodilatation/flushing
•  Respiratory, Thoracic and Mediastinal Disorders : Dyspnea, pharyngitis, rhinitis, cough, wheezing, 
throat tightness
• Skin and Subcutaneous Tissue Disorders : Stevens-Johnson syndrome
•  General Disorders and Administration Site Conditions : Pruritus, asthenia/fatigue, pain in extremities, 
chest pain
• Gastrointestinal Disorders : Vomiting
Other Events Reported During Post-Approval Use of Fluzone High-Dose.
• Gastrointestinal Disorders : Nausea, diarrhea
• General Disorders and Administration Site Conditions : Chills
DRUG INTERACTIONS
Data evaluating the concomitant administration of Fluzone High-Dose with other vaccines are not available. 
USE IN SPECIFIC POPULATIONS
Pregnancy: Pregnancy Category C: Animal reproduction studies have not been conducted with Fluzone 
High-Dose. It is also not known whether Fluzone High-Dose can cause fetal harm when administered to 
a pregnant woman or can affect reproduction capacity. Fluzone High-Dose should be given to a pregnant 
woman only if clearly needed. 
Pediatric Use: Safety and effectiveness of Fluzone High-Dose in persons <65 years of age have not 
been established.
Geriatric Use: Safety, immunogenicity, and efficacy of Fluzone High-Dose have been evaluated in adults 
65 years of age and older.
CLINICAL STUDIES
Immunogenicity of Fluzone High-Dose in Adults 65 Years of Age and Older
Study 1 (NCT00391053) was a multi-center, double-blind pre-licensure trial conducted in the US in which 
adults 65 years of age and older were randomized to receive either Fluzone High-Dose or Fluzone (2006-
2007 formulation). The study compared the safety and immunogenicity of Fluzone High-Dose to those of 
Fluzone. For immunogenicity analyses, 2576 participants were randomized to Fluzone High-Dose and 1275 
participants were randomized to Fluzone. Females accounted for 51.3% of participants in the Fluzone High-
Dose group and 54.7% of participants in the Fluzone group. In both groups, the mean age was 72.9 years 
(ranged from 65 through 97 years in the Fluzone High-Dose group and 65 through 94 years in the Fluzone 
group); 35% of participants in the Fluzone High-Dose group and 36% of participants in the Fluzone group 
were 75 years of age or older. Most participants in the Fluzone High-Dose and Fluzone groups, respectively, 
were White (91.7% and 92.9%), followed by Hispanic (4.8% and 3.7%), and Black (2.7% and 2.7%).
The primary endpoints of the study were hemagglutination inhibition (HI) GMTs and seroconversion rates 
28 days after vaccination. Pre-specified statistical superiority criteria required that the lower limit (LL) of the 
2-sided 95% CI of the GMT ratio (Fluzone High-Dose/Fluzone) be greater than 1.50 for at least two of the 
strains, and if one strain failed, non-inferiority of that strain must be demonstrated (LL>0.67), and that the 
lower limit of the 2-sided 95% CI of the seroconversion rate difference (Fluzone High-Dose minus Fluzone) 
be greater than 10% for at least two of the strains, and if one strain failed, non-inferiority of that strain must 
be demonstrated (LL>-10%). As shown in Table 2, statistically superior HI GMTs and seroconversion rates 
after vaccination with Fluzone High-Dose compared to Fluzone were demonstrated for influenza A subtypes, 
A (H1N1) and A (H3N2), but not for influenza type B. For strain B, non-inferiority of Fluzone High-Dose
compared to Fluzone was demonstrated for both the HI GMTs and seroconversion rates. 
Table 2: Study 1a: Post-Vaccination HI Antibody GMTs and Seroconversion Rates and Analyses 
of Superiority of Fluzone High-Dose Relative to Fluzone, Adults 65 Years of Age and Older
Influenza 
Strain




























A (H1N1) 115.8 67.3 1.7 
(1.6; 1.8)
48.6 23.1 25.4 
(22.4; 28.5) Yes
A (H3N2) 608.9 332.5 1.8 
(1.7; 2.0)
69.1 50.7 18.4 
(15.1; 21.7) Yes
B 69.1 52.3 1.3 
(1.2; 1.4)
41.8 29.9 11.8 
(8.6; 15.0) No
a   NCT00391053
b  Seroconversion: Paired samples with pre-vaccination HI titer <1:10 and post-vaccination (day 28) titer 
≥1:40 or a minimum 4-fold increase for participants with pre-vaccination titer ≥1:10
c N is the number of vaccinated participants with available data for the immunologic endpoint listed
d  Predefined superiority criterion for seroconversion: the lower limit of the two-sided 95% CI of the 
difference of the seroconversion rates (Fluzone High-Dose minus Fluzone) is >10%. Predefined 
superiority criterion for the GMT ratio: the lower limit of the 95% CI of the GMT ratio (Fluzone High-
Dose divided by Fluzone) is >1.5
Efficacy of Fluzone High-Dose in Adults 65 Years of Age and Older
Study 2 (NCT01427309) was a multi-center, double-blind post-licensure efficacy trial conducted 
in the US and Canada in which adults 65 years of age and older were randomized (1:1) to receive 
either Fluzone High-Dose or Fluzone. The study was conducted over two influenza seasons 
(2011-2012 and 2012-2013); 53% of participants enrolled in the first year of the study were 
re-enrolled and re-randomized in the second year. The per-protocol analysis set for efficacy 
assessments included 15,892 Fluzone High-Dose recipients and 15,911 Fluzone recipients. 
The majority (67%) of participants in the per-protocol analysis set for efficacy had one or more 
high-risk chronic comorbid conditions. 
In the per-protocol analysis set, females accounted for 57.2% of participants in the Fluzone 
High-Dose group and 56.1% of participants in the Fluzone group. In both groups, the median 
age was 72.2 years (range 65 through 100 years). Overall, most participants in the study 
were White (95%); approximately 4% of study participants were Black, and approximately 6% 
reported Hispanic ethnicity.
The primary endpoint of the study was the occurrence of laboratory-confirmed influenza 
(as determined by culture or polymerase chain reaction) caused by any influenza viral type/
subtype in association with influenza-like illness (ILI), defined as the occurrence of at least one 
of the following respiratory symptoms: sore throat, cough, sputum production, wheezing, or 
difficulty breathing; concurrent with at least one of the following systemic signs or symptoms: 
temperature >99.0°F, chills, tiredness, headaches or myalgia. Participants were monitored 
for the occurrence of a respiratory illness by both active and passive surveillance, starting 2 
weeks post-vaccination for approximately 7 months. After an episode of respiratory illness, 
nasopharyngeal swab samples were collected for analysis; attack rates and vaccine efficacy 
were calculated (see Table 3). 
Table 3: Study 2a: Relative Efficacy Against Laboratory-Confirmed Influenzab Regardless of 
Similarity to the Vaccine Components, Associated with Influenza-Like Illnessc, Adults 65 










Any type/subtypef 227 (1.43) 300 (1.89) 24.2 (9.7; 36.5)g
Influenza A 190 (1.20) 249 (1.56) 23.6 (7.4; 37.1)
A (H1N1) 8 (0.05) 9 (0.06) 11.0 (-159.9; 70.1)
A (H3N2) 171 (1.08) 222 (1.40) 22.9 (5.4; 37.2)
Influenza Bh 37 (0.23) 51 (0.32) 27.4 (-13.1; 53.8)
a NCT01427309
b Laboratory-confirmed: culture- or polymerase-chain-reaction-confirmed 
c  Occurrence of at least one of the following respiratory symptoms: sore throat, cough, sputum 
production, wheezing, or difficulty breathing; concurrent with at least one of the following 
systemic signs or symptoms: temperature >99.0°F, chills, tiredness, headaches or myalgia
d N is the number of vaccinated participants in the per-protocol analysis set for efficacy assessments
e  n is the number of participants with protocol-defined influenza-like illness with laboratory 
confirmation
f Primary endpoint
g  The pre-specified statistical superiority criterion for the primary endpoint (lower limit of the 2-sided 
95% CI of the vaccine efficacy of Fluzone High-Dose relative to Fluzone >9.1%) was met.
h  In the first year of the study the influenza B component of the vaccine and the majority of influenza B 
cases were of the Victoria lineage; in the second year the influenza B component of the vaccine and 
the majority of influenza B cases were of the Yamagata lineage
A secondary endpoint of the study was the occurrence of culture-confirmed influenza caused by viral 
types/subtypes antigenically similar to those contained in the respective annual vaccine formulations 
in association with a modified CDC-defined ILI, defined as the occurrence of a temperature 
>99.0°F (>37.2°C) with cough or sore throat. The efficacy of Fluzone High-Dose relative to Fluzone 
for this endpoint was 51.1% (95% CI: 16.8; 72.0).
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HOW SUPPLIED/STORAGE AND HANDLING 
How Supplied
Single-dose, prefilled syringe, without needle, 0.5 mL (NDC 49281-399-88) (not made with natural 
rubber latex). Supplied as package of 10 (NDC 49281-399-65).
Storage and Handling
Store Fluzone High-Dose refrigerated at 2° to 8°C (35° to 46°F). DO NOT FREEZE. Discard if vaccine 
has been frozen. Do not use after the expiration date shown on the label.
PATIENT COUNSELING INFORMATION 
See FDA-approved patient labeling (Patient Information). 
•  Inform the patient or caregiver that Fluzone High-Dose contains killed viruses and cannot 
cause influenza.
•  Among persons aged 65 years and older, Fluzone High-Dose stimulates the immune system to 
produce antibodies that help protect against influenza.
•  Among persons aged 65 years and older, Fluzone High-Dose offers better protection against
influenza as compared to Fluzone.
• Annual influenza vaccination is recommended.
•  Instruct vaccine recipients and caregivers to report adverse reactions to their healthcare provider 
and/or to Vaccine Adverse Event Reporting System (VAERS).
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